There is increasing appreciation of the key role that the intestinal microbiome plays in preventing the colonization and overgrowth of pathogens^[@R1],[@R2]^. The mechanisms that have been implicated in this beneficial function of probiotic bacteria are mostly indirect and include modulation of the immune system, enhancement of the intestinal epithelial barrier, or competition with pathogens for nutrients^[@R2]--[@R5]^. Whether there is direct interference between probiotic and pathogenic bacteria is less clear. Some probiotic strains produce bacteriocins, which can kill phylogenetically related pathogenic bacteria^[@R2]^, and it has been shown that a bacteriocin-producing *Escherichia coli* strain inhibited colonization with related pathogenic bacteria in the inflamed gut of mice^[@R6]^. However, no evidence has been obtained to indicate that such mechanisms matter or are widespread in humans. Furthermore, it is not known whether there are ways of direct probiotic bacterial interference that are not mediated by bacteriocins.

The genus *Bacillus* comprises different species of soil bacteria that form endospores with the ability to survive harsh environmental conditions, such as the high temperatures encountered during cooking procedures. *Bacillus* spores are commonly ingested with vegetables^[@R7]^. They can subsequently germinate to form metabolically active, vegetative cells^[@R8]^, which can temporarily colonize the intestinal tract^[@R9]^. Given the dependence on dietary customs, the concentration of *Bacillus* spores in human feces is highly variable. It has been reported to be \~ 10^5^ CFU/g in average, occasionally reaching up to 10^8^ CFU/g^[@R7]^. Several probiotic formulae contain *Bacillus* species^[@R10]^, which are believed to reduce pathogen colonization by mechanisms that - except for a described immune-stimulatory effect on epithelial cells^[@R11]^ - remain poorly defined.

*Staphylococcus aureus* is a widespread and dangerous human pathogen that can cause a variety of diseases, ranging from moderately severe skin infections to fatal pneumonia and sepsis^[@R12]^. Treatment of *S. aureus* infections is severely complicated by antibiotic resistance^[@R13]^, such as in methicillin-resistant *S. aureus* (MRSA), and there is no working *S. aureus* vaccine^[@R14]^. Therefore, alternative strategies to combat *S. aureus* infections are eagerly sought^[@R15]^. Because *S. aureus* infections commonly originate from previous asymptomatic colonization^[@R16],[@R17]^, decolonization has recently gained considerable attention as a possible means to fight *S. aureus* infections in a preventive manner^[@R18]^. While the nares have traditionally been considered the primary *S. aureus* colonization site^[@R19]^, there is increasing evidence indicating that the intestinal tract is also commonly colonized by *S. aureus*^[@R20]--[@R22]^ and forms an important reservoir for *S. aureus* infectious disease outbreaks^[@R23],[@R24]^. Several studies have reported levels of *S. aureus* in the feces of human adults of \~ 10^3^ - 10^4^ CFU/g^[@R25]--[@R27]^. Possibly, intestinal *S. aureus* colonization explains the failure of previous topical decolonization efforts aimed solely at the nose^[@R16],[@R22],[@R28]^.

Here, we hypothesized that the composition of the human gut microbiota affects intestinal colonization with *S. aureus*. To evaluate that hypothesis, we collected fecal samples from 200 healthy individuals from rural populations in Thailand ([Fig. 1a](#F1){ref-type="fig"}). This exemplary population was selected to rule out, as much as possible, food sterilization and antibiotic presence as used frequently in highly developed urban areas, which potentially could diminish the abundance of probiotic bacteria in the food and the intestinal tract of the participating subjects. Our analysis revealed a comprehensive *Bacillus*-mediated *S. aureus* exclusion effect in the human population. By demonstrating that quorum-sensing is indispensable for *S. aureus* intestinal colonization and discovering that secreted *Bacillus* fengycin lipopeptides function as quorum-sensing blockers to achieve complete eradication of intestinal *S. aureus*, we provide evidence strongly suggesting that this pathogen exclusion effect in humans is due to a widespread and efficient probiotic-mediated mechanism that inhibits pathogen quorum-sensing signaling.

*S. aureus* exclusion by *Bacillus* {#S1}
===================================

*S. aureus* intestinal carriage as determined by growth from fecal samples was found in 25/200 (12.5%) of human subjects. Nasal carriage was similar in frequency (26/200; 13%), a result that is in accordance with previous findings showing a correlation between nasal and intestinal colonization^[@R22]^. These rates are considerably lower than those commonly found in adult populations during cross-sectional culture-based surveys that were mainly performed in hospital-admitted individuals in urbanized areas (on average, \~ 20% for intestinal and \~ 40% for nasal carriage)^[@R16],[@R21],[@R22]^.

To examine the hypothesis that bacterial interactions in the gut determine intestinal *S. aureus* colonization, we first analyzed the composition of the gut microbiome by 16S rRNA sequencing. However, we did not detect significant differences in the composition of the microbiome between *S. aureus* carriers and non-carriers ([Extended Data Fig. 1](#T1){ref-type="table"}).

In contrast, we found a striking correlation between the presence of *Bacillus* bacteria and absence of *S. aureus*. *Bacillus* species (mostly *B. subtilis*, [Extended Data Fig. 1](#T1){ref-type="table"}) were found in 101/200 (50.5%) of subject samples. *S. aureus* was never detected in fecal samples when *Bacillus* species were present (p\<0.0001, Fisher's exact test) ([Fig. 1b](#F1){ref-type="fig"}). Furthermore, this pathogen exclusion effect was not limited to the site of interaction, the gut, but extended to *S. aureus* colonization in a general fashion. While *Bacillus* was generally absent from nasal samples, *S. aureus* nasal colonization was never detected in the presence of intestinal *Bacillus* (p\<0.0001, Fisher's exact test) ([Fig. 1c](#F1){ref-type="fig"}). Interestingly, the levels of *S. aureus* colonization we found in non-*Bacillus*-colonized individuals from rural Thailand approximately match those reported, using similar culture-based assays, in urbanized Western areas. These findings indicate a widespread mechanism exerted by *Bacillus* species that comprehensively inhibits colonization with *S. aureus*. Moreover, they suggest that *S. aureus* colonization is increased in urban populations due to the lack of a probiotic, *Bacillus-*containing diet. Intriguingly, they also imply that the intestinal site plays a previously underappreciated role in determining general *S. aureus* colonization, a notion in accordance with findings attributing a key role to fecal transmission in MRSA re-colonization^[@R28]^.

When we analyzed data from previous 16S rRNA-sequencing-based microbiome studies, we found strongly variant results and no correlation between the absence of *S. aureus* and the presence of *B. subtilis*: Studies that reported considerable *B. subtilis* or *S. aureus* numbers (samples with colonization by either species \> 10%) did not reveal exclusion phenomena (average 14.89 ± 15.69% colonization by both species) ([Extended Data Fig. 2](#T2){ref-type="table"}). While we did not find a correlation, we feel this may be due to the fact that such sequencing-based analyses are set up to detect high-order taxonomic shifts rather than specific differences on the species or genus level.

Quorum-sensing and colonization {#S2}
===============================

Our results showing no significant high-order taxonomic differences in the microbiome composition between *S. aureus* carriers and non-carriers exclude an indirect effect of *Bacillus* on the microbiome composition. Rather, we hypothesized that the *Bacillus* isolates produce a substance that directly and specifically inhibits *S. aureus* intestinal colonization. We first analyzed whether there is a growth-inhibitory effect of the *Bacillus* isolates on *S. aureus*. However, only a minor growth inhibition occurred in 6 out of 105 isolates (maximally 1 mm inhibition zone when analyzed using an agar diffusion test with five-times concentrated culture filtrate). This fails to explain the observed complete correlation between the presence of *Bacillus* and absence of *S. aureus*, and rules out a bacteriocin-mediated phenomenon.

It is poorly understood which factors are important for *S. aureus* intestinal colonization. Only one mouse study implicated wall teichoic acids and the surface protein, clumping factor A (ClfA)^[@R29]^. Prompted by our previous finding that ClfA is positively regulated by the Agr quorum-sensing system^[@R30]^, we hypothesized that the *Bacillus* isolates secrete a substance that interferes with quorum-sensing signaling. Quorum-sensing is responsible for sensing the density of the bacterial population ("quorum") and controlling the concomitant alteration of cell physiology^[@R31]^. As quorum-sensing signals and sensors differ between different types of bacteria^[@R31]^, an underlying quorum-quenching mechanism would explain the specificity of the inhibitory effect that we detected.

Because the role of quorum-sensing in *S. aureus* intestinal colonization is unknown, we first used a mouse model of *S. aureus* intestinal colonization to test whether Agr quorum-sensing plays a role ([Fig. 2a](#F2){ref-type="fig"}). In all mouse models in our study, we included (i) a human fecal isolate belonging to a sequence type (ST) frequently detected in the obtained fecal isolates (ST2196), according to multi-locus sequence typing (MLST) we performed ([Supplementary Tab. 1](#SD3){ref-type="supplementary-material"}), (ii) a mouse infection isolate (ST88)^[@R32]^, and (iii) a human infection isolate of the highly virulent MRSA type USA300^[@R33]^. In competition experiments with equal amounts of wild-type and isogenic *agr* mutant strains, only wild-type *S. aureus* were detected in the feces and colonized the large and small intestines at the end of the experiment (competition index ≥ 100) ([Fig. 2b](#F2){ref-type="fig"}, [Extended Data Fig. 2 a,b](#F7){ref-type="fig"}). Furthermore, in a non-competitive experimental setup, only those bacteria expressing the intracellular Agr effector RNAIII^[@R34]^ achieved colonization, while *agr*-negative control strains never did ([Fig. 2c](#F2){ref-type="fig"}, [Extended Data Fig. 2c](#F7){ref-type="fig"}). These data show that in addition to its well-known role in infection^[@R30],[@R35]^, the Agr quorum-sensing system is absolutely indispensable for intestinal colonization.

Fengycin quorum-quenchers {#S3}
=========================

Having established that the Agr quorum-sensing regulatory system is essential for *S. aureus* intestinal colonization, we analyzed whether culture filtrates of the *Bacillus* isolates collected from human feces can inhibit Agr. To that end, we used an *S. aureus* reporter strain, in which we had transferred the luminescence-conferring *luxABCDE* operon into the genome under control of the Agr P3 promoter^[@R34]^, which controls production of RNAIII. Remarkably, culture filtrates from all 105 isolates reduced Agr activity in that assay by at least 80% ([Fig. 3a](#F3){ref-type="fig"}, [Extended Data Tab. 1](#T1){ref-type="table"}). No growth effects were observed, substantiating that growth inhibition does not underlie the inhibitory phenotype. Furthermore, culture filtrate from a reference *B. subtilis* strain suppressed the production of key Agr-regulated virulence factors (phenol-soluble modulins, α-toxin, and Panton-Valentine leukocidin) ([Fig. 3b,c](#F3){ref-type="fig"}, [Supplementary Fig. 1](#SD3){ref-type="supplementary-material"} ). These results indicated that the inhibitory effect of the *Bacillus* isolates on *S. aureus* colonization is due to a secreted substance that inhibits Agr signaling.

To characterize the Agr-inhibitory substance, we performed experiments with culture filtrate of the reference *B. subtilis* strain. The substance in question was thermostable and resistant to protease digestion ([Extended Data Fig. 3 a](#F8){ref-type="fig"}). In reversed-phase high performance chromatography (RP-HPLC) ([Extended Data Fig. 3b](#F8){ref-type="fig"}), significant Agr-inhibiting activity was associated with two peaks, which we then analyzed by RP-HPLC/electrospray ionization mass spectrometry (ESI-MS) ([Extended Data Fig. 3c](#F8){ref-type="fig"}). This analysis, together with the elution behavior and published literature^[@R36]^, allowed us to identify the substances as members of the fengycin cyclic lipopeptide family. Because fengycins can differ in specific amino acids in addition to the length of the attached fatty acid, which usually is β-hydroxylated (β-OH), and different *Bacillus* strains produce somewhat different fengycin species^[@R37]^, we used further tandem mass spectrometric fragmentation analysis (MS/MS) to identify the specific fengycins present in the two active peaks ([Extended Data Fig. 3d](#F8){ref-type="fig"}). Fengycins in the first peak were identified as β-OH-C17-fengycin A and β-OH-C16-fengycin B. The second peak consisted of one fengycin species, β-OH-C17-fengycin B. Smaller, adjacent peaks also contained fengycin species according to RP-HPLC/ESI-MS analysis, which we tentatively identified as β-OH-C17-fengycin A and the de-hydroxylated versions of the identified three major fengycins ([Extended Data Fig. 3e](#F8){ref-type="fig"}). For further analyses, higher amounts of β-OH-C17-fengycin B were purified to homogeneity from culture filtrate and dose-dependent Agr-inhibiting activity of this pure substance was verified ([Extended Data Fig. 4](#F9){ref-type="fig"}).

Using RP-HPLC/ESI-MS analysis, we found fengycin production in all isolates, substantiating the general character of the inhibitory interaction ([Extended Data Tab. 1](#T1){ref-type="table"}). While the production pattern of different fengycins varied in the analyzed isolates, in many of them β-OH-C17-fengycin B was the most strongly produced type. Notably, almost complete inhibition of Agr was detected at a concentration of \~ 1.4 μM total fengycin ([Fig. 3d](#F3){ref-type="fig"}). This corresponds to the median concentration of total fengycin produced by stationary phase-cultures of the *Bacillus* isolates (1.5 μM) ([Fig. 3e](#F3){ref-type="fig"}).

To provide definitive evidence that fengycin production underlies the Agr-inhibiting capacity of *Bacillus*, we produced an isogenic mutant in the reference *B. subtilis* strain of the *fenA* gene, which is essential for fengycin production^[@R38]^. RP-HPLC/ESI-MS showed specific absence of fengycins in that mutant strain, while surfactins, the predominant *Bacillus* lipopeptides, were still present ([Extended Data Fig. 3f](#F8){ref-type="fig"}). Culture filtrate of the *fenA* mutant strain was devoid of Agr-inhibiting activity in contrast to that of the isogenic wild-type strain ([Fig. 3f](#F3){ref-type="fig"}). We also measured an isogenic surfactin-negative mutant strain, which showed Agr-inhibiting activity similar to the wild-type strain ([Fig. 3f](#F3){ref-type="fig"}). These results confirmed that fengycin production is the source of the observed Agr inhibition.

Mechanism of fengycin inhibition {#S4}
================================

In the *S. aureus* Agr quorum-sensing regulatory circuit, the secreted Agr autoinducing-peptide (AIP) interacts with an extracellular domain of AgrC, the histidine kinase part of a two-component signal transduction system, to signal the cell density status ([Fig. 4a](#F4){ref-type="fig"})^[@R39]^. Different Agr subgroups of *S. aureus*, as well as different staphylococcal species, produce cyclic hepta- to nonapeptide AIPs^[@R35]^. AIPs from different subgroups or species frequently inhibit Agr signal transduction by competitive inhibition at the AgrC binding site^[@R39]--[@R41]^. Given that fengycins as cyclic lipopeptides show structural similarity to AIPs ([Fig. 4b](#F4){ref-type="fig"}), it appears likely that fengycins compete with the natural AIP for AgrC binding. The only other theoretically possible site of interference from the extracellular space would be the membrane-located AIP production/secretion enzyme AgrB. Using an *S. aureus agrBD* deletion strain and stimulation of AgrC by synthetic AIP, which led to complete Agr inhibition, we ruled out that the target of Agr inhibition by *Bacillus* is AgrB ([Fig. 4c](#F4){ref-type="fig"}). In further support of a mechanism that works by competition with AIP for binding to the AgrC receptor, fengycin inhibition could be reversed in a dose-dependent fashion by addition of AIP ([Fig. 4d](#F4){ref-type="fig"}). Finally, we determined the AIP concentration in early stationary growth phase (6--8 h) to be \~ 1 μM (**[Extended Data Fig. 5a](#F10){ref-type="fig"}**), which is approximately equal to the concentration of fengycin for which we found complete Agr inhibition ([Fig. 3d](#F3){ref-type="fig"}). These findings indicate that fengycins inhibit Agr signal transduction by efficient competitive inhibition as structural analogues of AIPs.

The fact that AgrC-AIP interaction differs by Agr subtype raises the question whether fengycins have general ability to inhibit Agr. We found that purified β-OH-C-17 fengycin B inhibited Agr in members of all *S. aureus* Agr subtypes, as well as in *S. epidermidis* ([Fig. 4e](#F4){ref-type="fig"}). Furthermore, the *S. aureus* strains used in the mouse experiments belong to different Agr subtypes (USA300, type I, ST88, type III, ST2196, type I). These results indicate that fengycins have broad-spectrum Agr-inhibiting activity.

*Bacillus* spores eradicate *S. aureus* {#S5}
=======================================

To validate our findings *in vivo* and demonstrate the specific role of fengycins in the inhibition of *S. aureus* intestinal colonization, we compared the impact of the *B. subtilis* wild-type reference strain and its isogenic *fenA* mutant on *S. aureus* colonization in a mouse intestinal colonization model. We first performed a control experiment analyzing the colonization kinetics of *B. subtilis* when given as spores, which corresponds to the form *Bacillus* would be taken up with food or probiotic formulae ([Extended Data Fig. 5b](#F10){ref-type="fig"}). We observed transient colonization that strongly declined within two days. Importantly, colonization by the *fenA* mutant was not different from that by the *B. subtilis* wild-type strain, ruling out that fengycin production per se impacts *B. subtilis* colonization.

Feeding mice *B. subtilis* spores completely abrogated colonization of all tested *S. aureus* strains in the feces and intestines, in experimental setups with or without antibiotic pre-treatment to eliminate the pre-existing microbiota. ([Fig. 5b,c](#F5){ref-type="fig"}, [Extended Data Fig. 5c-f](#F10){ref-type="fig"}). In contrast, spores of the *fenA* mutant had no significant effect on colonization of any *S. aureus* test strain. As *Bacillus* intestinal colonization in humans has been shown to reach much higher levels than that by *S. aureus*^[@R7]^, a situation highly likely to be even more pronounced in the tested rural population, our mouse data obtained with *S. aureus* numbers approximately equaling or exceeding those of applied *Bacillus* spores suggest that fengycin-mediated quorum-sensing interference contributes to the *S. aureus* colonization exclusion we observed in humans.

Conclusions {#S6}
===========

Scientific evidence to support the frequent claims that probiotic nutrients improve human health is scarce. This study provides evidence for a molecular mechanism of probiotic food bacteria-mediated direct interference that limits pathogen colonization. In particular, our data underscore the often-debated^[@R10],[@R42]^ probiotic value of *B. subtilis*. Interestingly, we found the responsible agents to work by quorum-quenching, demonstrating that pathogen exclusion in the gut may work by inhibition of a pathogen signaling system. Furthermore, our findings emphasize the importance of quorum-sensing for pathogen colonization.

Our study suggests several highly valuable translational applications regarding alternative strategies to combat antibiotic-resistant *S. aureus*. First, the quorum-quenching fengycins, which previously had only been known for their anti-fungal activities^[@R43]^, may be used as quorum-sensing blockers for eagerly sought antivirulence-based efforts to treat staphylococcal infections^[@R15],[@R44]^. Second, *Bacillus*-containing probiotics may be used for simple and safe *S. aureus* decolonization strategies. In that regard, it is particularly noteworthy that our human data indicate that probiotic *Bacillus* can comprehensively eradicate intestinal as well as nasal *S. aureus* colonization. Such a probiotic approach would have multiple advantages over the current standard topical strategy with antibiotics, which is aimed exclusively at decolonizing the nose^[@R45]^.

Methods {#S7}
=======

No statistical methods were used to predetermine sample size. The experiments were not randomized, and the investigators were not blinded to allocation during experiments and outcome assessment, except for when noted.

Sample collection and bacterial screening {#S8}
-----------------------------------------

Nasal swabs and fecal samples were obtained from 200 Thai healthy volunteers from four different locations in southern, central, northeastern, and northern Thailand. One sterile nasal swab, a sample collection tube, a sterile container, and tissue paper were given to each participant. All participants provided informed written consent. The study was performed in compliance with all relevant ethical regulations and approved by the Siriraj Institutional Review Board (approval no. Si 733/2015). All participants were over 20 years old (age range: 20--87, median 57±14.5; 131 women and 69 men) and without history of intestinal disease. None had received any antibiotic treatment or stayed at a hospital within at least three months prior to the study. Nasal swabs and fecal samples were streaked on mannitol salt agar (MSA) and then incubated at 37 °C for 24 hours. Positive or negative *S. aureus* or *Bacillus* colonization could easily be distinguished by either strong growth on the entire plate, or absence of any colonies, respectively. At the time of this analysis, the purpose of the analysis was to obtain and archive colonizing *S. aureus* strains. As the hypothesis on *Bacillus*-S*. aureus* exclusion was only developed from the results of this analysis, the staff performing the analysis were blinded as for the exclusion hypothesis. Isolates were easily recognized as *S. aureus* or *Bacillus* by colony morphology and color; however, every isolate was confirmed for species identity using matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) (see below), and *Bacillus* species were also further distinguished by 16S rRNA sequencing ([Extended Data Tab. 1](#T1){ref-type="table"}). To that end, 16S rRNA genes were PCR-amplified using primers 27FB and 1492RAB^[@R46]^ and BLAST similarity analysis was used to identify the species. Subjects were considered as permanently colonized by *S. aureus* if two positive samples were obtained, tested in a 4-week interval. All individuals tested either negative or positive for *S. aureus* at both times. In total, 105 *Bacillus* isolates from 101 individuals were analyzed. In the samples from four individuals, two isolates each were taken due to apparent phenotypic differences.

Bacterial identification using MALDI-TOF MS {#S9}
-------------------------------------------

Isolates were inoculated onto sheep blood agar and incubated for 24 h at 37 °C. Bacterial colonies were applied onto a 96-spot target plate and allowed to dry at room temperature. Subsequently, 2 μl of MALDI matrix \[a saturated solution of α-cyano-4-hydroxycinnamic acid (HCCA) in 50% acetonitrile and 2.5% trifluoroacetic acid\] was applied onto the colonies and allowed to dry before testing. Then the target plate was loaded into the MALDI-TOF MS instrument (MicroFlex LT mass spectrometer, Bruker Daltonics). Spectra were analyzed using MALDI Biotyper automation control and the Bruker Biotyper 2.0 software and library (version 2.0, 3,740 entries; Bruker Daltonics). Identification score criteria used were those recommended by the manufacturer: a score of ≥ 2.000 indicated species-level identification, a score of 1.700 to 1.999 indicated identification to the genus level, and a score of \<1.700 was interpreted as no identification. Isolates that failed to produce a score of \<1.700 with direct colony or extraction methods were retested. *S. aureus* ATCC25923, *E. coli* ATCC25922 and *Pseudomonas aeruginosa* ATCC27853 were used as controls.

Bacterial strains and growth conditions {#S10}
---------------------------------------

The reference *B. subtilis* strain and parent of the *fenA* and *srfA* mutants used in this study was strain ZK3814 (genotype NCIB3610). The *S. aureus* strains used in all experiments (except the experiment analyzing different Agr-subtype *S. aureus*) were (i) the human fecal isolate F12 of ST2196 ([Supplementary Tab. 1](#SD3){ref-type="supplementary-material"}), (ii) strain JSNZ of ST88, a mouse isolate previously described as mouse-adapted^[@R32]^, (iii) strain LAC of pulsed-field type USA300, an MRSA lineage predominantly involved in community-associated infections, but now generally representing the major lineage responsible for *S. aureus* infections in the United States^[@R47]^.

Isogenic mutants in *agr* were previously described (for strain LAC)^[@R48]^ or produced in this study (for strains JSNZ and F12) by phage transduction of the *agr* deletion from strain RN6911. The *agr* system is entirely deleted in these strains, except for a 3' part of RNAIII, which is not transcribed owing to the absence of the corresponding promoter. All mutants were verified by analytical PCR.

Due to the tetracycline resistance introduced in the *agr* deletion strains, kanamycin derivatives (pKX~Δ~) of the pTX~Δ~ expression plasmid series were constructed and used for complementation of Agr. (This was not possible in strain LAC, which harbors multiple antibiotic resistance including to kanamycin). To that end, plasmid pKX15^[@R49]^ kindly provided by B. Krismer, University of Tübingen, was treated as described^[@R48]^ to delete the *xylR* promoter to make expression of any fragment cloned under control of the *xyl* promoter constitutive. To obtain plasmid pKX~Δ~RNAIII, the RNAIII BamH1-MluI fragment was transferred from pTX~Δ~RNAIII^[@R50]^. Plasmid pTX~Δ~16 is the corresponding empty control plasmid.

To construct the *agrBD* deletion mutant of strain LAC P3-*lux*, a 4.8 kb-PCR product from USA300 genomic DNA that included the *agrBDCA* operon, 1 kb upstream, and 1 kb downstream, was cloned into the SmaI site of pIMAY^[@R51]^ and inverse PCR was used to delete *agrBD*. Allelic exchange was then performed, and the chromosomal deletion was confirmed by PCR using one primer outside of the 1 kb homology arm, followed by sequencing the PCR product. See [Supplementary Table 2](#SD3){ref-type="supplementary-material"} for oligonucleotides used.

To construct the tetracycline--resistant derivatives of *S. aureus* ST88 and ST2196, φ11 phage-mediated transduction was performed as described to transfer the tetracycline cassette in the donor strain (*S. aureus* RN4220 with integrated pLL29) to *S. aureus* ST88 and ST2196^[@R52]^.

To construct the *B. subtilis* fengycin mutant strain, SPP1 phage-mediated transduction^[@R53]^ was performed to transfer the *fenA* deletion present in the donor strain (BKE18340 -- a *fenA(ppsA)::erm* mutant in *B. subtilis* 168 obtained from the *Bacillus* Genetic Stock Center) to *B. subtilis* ZK3814. This was necessary as *B. subtilis* 168 bears a mutation in the *sfp* gene abolishing lipopeptide production.

Bacteria were generally grown in tryptic soy broth (TSB) with shaking unless otherwise indicated.

Typing of *S. aureus* isolates {#S11}
------------------------------

*S. aureus* isolates were typed by multi-locus sequence typing (MLST) as previously described^[@R54]^. PCR amplicons of seven *S. aureus* housekeeping genes (*arcC*, *aroE*, *glpF*, *gmk*, *pta*, *tpi*, and *yqiL*) were obtained from chromosomal DNA and their sequences compared with those available at the PubMLST database (<https://pubmlst.org/saureus/>). Not previously described alleles (*arcC* 520--521 and *gmk* 337) and STs (STs 4630 -- 4638) were deposited to the website. The Agr subtype of *S. aureus* isolates was determined using a modified multiplex qRT-PCR protocol^[@R55]^. Two duplex qRT-PCR protocols using the respective described primer sets and two colored probes each were set up for Agr types I and II, and III and IV, respectively. Isolates whose Agr type could not be determined by that method were analyzed for the type of AIP production using HPLC/MS with the chromatography method also used for PSM detection (see below), integrating the three major m/z peaks for each AIP type.

Microbiome analysis {#S12}
-------------------

Genomic DNA from each fecal sample was extracted using a QIAamp DNA stool Minikit (Qiagen) according to the manufacturer's instructions. The DNA was quantified using a Nanodrop spectrophotometer and 16S rRNA paired-end sequencing of the V4 region of 16S rRNA was performed by Illumina (San Diego, California) using an Illumina MiSeq system as described^[@R56]^.

For all obtained paired-end sequences, the abundance of Operational Taxonomic Units (OTU) and alpha and beta diversity were identified using Quantitative Insights Into Microbial Ecology (QIIME 1.9.1)^[@R57]^. This study used the Nephele (release 1.6) platform from the National Institute of Allergy and Infectious Diseases (NIAID) Office of Cyber Infrastructure and Computational Biology (OCICB) in Bethesda, Maryland. The sequences were assigned to OTUs with the QIIME's uclust-based^[@R58]^ open-reference OTU picking protocol^[@R59]^ and the Greengenes 13_8 reference sequence set^[@R60]^ at 99% similarity. Alpha diversity was calculated using Chao1 and Shannon analyses^[@R61]^ and compared across groups using a nonparametric *t* test with 999 permutations.

Growth inhibition analysis {#S13}
--------------------------

Growth inhibition of *S. aureus* by *Bacillus* culture filtrates was tested with an agar diffusion assay. To that end, 10 μl of *Bacillus* culture filtrate of each isolate was spotted on sterile filter disks. The filters were let to dry and the procedure was repeated four times, after which filters were laid on agar plates containing *S. aureus*, resulting in the analysis of five-times concentrated culture filtrate.

Fengycin purification {#S14}
---------------------

To identify the Agr-inhibiting active substance, 10 ml culture filtrate of the *B. subtilis* reference strain grown for 48 h in TSB were applied to a Zorbax SB-C18 9.4 mm x 25 cm reversed-phase column (Agilent) using an AKTA Purifier 100 system (GE Healthcare). After washing with three column volumes with 100% buffer A \[0.1% trifluoroacetic acid (TFA) in water\] and five column volumes of 30% buffer B (0.1% TFA in acetonitrile), a 20-column volume gradient from 30 to 100% buffer B was applied. The column was run at a flow rate of 3 ml/min. Peak fractionation was performed using the absorbance at 214 nm and fractions were subjected to further analysis by RP-HPLC/ESI-MS and MS/MS and test for Agr inhibition (see below).

To purify larger amounts of the main active peak containing β-OH-C17-fengycin B, acetonitrile was added to 200 ml filtrate from cultures grown under the same conditions to a final concentration of 10%, precipitated material was removed by centrifugation for 10 min at 3700 x *g* using a Sorvall Legend RT centrifuge, and the obtained cleared supernatant was applied to a self-packed HR 16/10 column filled with Resource PHE (GE Healthcare) material (column volume, 17 ml). After sample application, the column was washed with 10 % buffer B for three column volumes and 25% buffer B for five column volumes, after which a gradient of 15 column volumes from 25 to 60% buffer B was applied. 10-ml fractions were collected and positive fractions (as determined by RP-HPLC/MS) were lyophilized. The lyophilisate was redissolved in 2 ml acetonitrile. Six ml of water was added and the precipitated material was removed by 5 min centrifugation in a tabletop centrifuge at maximum speed. The cleared supernatant was then further purified on a Zorbax SB-C18 9.4 mm x 25 cm reversed-phase column as described above.

PSM and lipopeptide detection by RP-HPLC/MS {#S15}
-------------------------------------------

PSMs were analyzed by RP-HPLC/ESI-MS using an Agilent 1260 Infinity chromatography system coupled to a 6120 Quadrupole LC/MS in principle as described^[@R62]^, but with a shorter column and a method that was adjusted accordingly. A 2.1 × 5 mm Perkin-Elmer SPP C8 (2.7 μm) guard column was used at a flow rate of 0.5 ml/min. After sample injection, the column was washed for 0.5 min with 90% buffer A /10% buffer B, then for 3 min with 25% buffer B. Then, an elution gradient was applied from 25% to 100% buffer B in 2.5 min, after which the column was subjected to 2.5 min of 100% buffer B to finalize elution.

*Bacillus* culture filtrates or (partially) purified lipopeptide (fengycins, surfactins) containing fractions were analyzed using the same column, system, and elution conditions. To quantify production of different fengycins, the two most abundant peaks, corresponding to double and triple charged ions, were used for the integration. Agilent Mass Hunter Quantitative Analysis Version B.07.00 was used for quantification.

Measurement of Agr activity {#S16}
---------------------------

To determine the Agr-inhibiting activity of *Bacillus* culture filtrates or purified fractions, we measured luminescence emitted by an Agr P3 promoter-*luxABCDE* reporter fusion construct that was inserted into the genome of strain *S. aureus* LAC^[@R34]^. Strain LAC P3-*luxABCDE* was diluted 100-fold from a pre-culture grown overnight in TSB before distribution into a 96-well microtiter plate. To 100 μl of that dilution, 100 μl of sterilized culture filtrate sample was added, unless otherwise indicated. Plates were incubated at 37°C with shaking. Luminescence was measured with a GloMax Explorer luminometer (Promega) every 2 h for a total of 6 h. Inhibition was considered significant if the 4-h sample and control values differed by at least a factor of 2. Of note, the quorum-quenching effect exerted by the one-time initial dose of fengycin or fengycin-containing culture filtrates was transient and was overcome at later times by the increasing intrinsic AIP production. Agr-inhibiting activity of purified fengycin was also measured using quantitative real-time PCR of RNAIII as described previously^[@R30]^.

To determine the Agr-inhibiting activity on target strains other than LAC (Agr subtype I), the impact on the production of δ-toxin, whose gene is embedded in the Agr intracellular effector RNA, RNAIII, in most staphylococci, was used. Production of δ-toxin was measured by RP-HPLC/ESI-MS as described above. Strains LAC (Agr subtype I), A950085 (Agr subtype II), MW2 (Agr subtype III), and A970377 (Agr subtype IV) were used for testing the effect of β-OH-C17-fengycin B on *S. aureus* of different Agr subgroups. Strain 1457 was used for *S. epidermidis*. All strains were diluted 100-fold from a pre-culture grown in TSB. β-OH-C17-fengycin B dissolved in DMSO was added to each sample to a final concentration of 20 and 100 μM. All samples were incubated at 37 °C with shaking for 4 h. Samples were centrifuged and supernatant was collected for RP-HPLC/MS detection.

Analysis of PVL and α−toxin expression {#S17}
--------------------------------------

*S. aureus* strain LAC was diluted 100-fold from a pre-culture grown in TSB and inoculated into 500 μl TSB. Two hundred and fifty μl of *B. subtilis* culture filtrate was added into the sample. Samples were incubated at 37 °C with shaking for 4 h. Samples were centrifuged in a tabletop centrifuge at maximum speed for 5 min; the supernatants were collected and loaded onto 12% SDS-PAGE gels, which were run at 160 V for 1 h. Proteins were transferred to nitrocellulose membranes using an iBlot Western blotting system. Membranes were incubated with Odyssey blocking buffer for 1 h at room temperature. Anti-α-toxin (polyclonal rabbit serum; Sigma S7531; dilution 1:5,000) or anti-LukF-PV (affinity-purified rabbit IgG specific for a peptide region of LukF-PV, produced by GenScript USA Inc. and kindly provided by F. DeLeo, NIAID; dilution 1:500) antibodies were added to the blocking buffer and membranes were incubated overnight at 4 °C. Then, membranes were washed five times with Tris-buffered saline containing 0.1% Tween-20, pH 7.4 and incubated with Cy5-labeled goat anti-rabbit IgG (diluted 1:10,000 in blocking buffer) in the dark for 1 h at room temperature. Membranes were washed five times with the washing buffer and scanned with a Typhoon TRIO+ Variable Mode Imager.

Preparation of *Bacillus* spores {#S18}
--------------------------------

*B. subtilis* wild-type or isogenic fengycin mutant strains were inoculated from a pre-culture (1:100) into 1 l of 2 x SG medium^[@R63]^ and allowed to sporulate for 96 hours. Cells were pelleted, washed with water, and resuspended in 20% metrizoic acid (Sigma). Five different concentrations (w/v) of metrizoic acid (60% - 20%) were added stepwise to a 50-ml centrifuge tube to obtain a density gradient. Then, a cell suspension was added to the top of the gradient, followed by centrifugation at 40,000 × *g* for 60 min at 4 °C^[@R64]^. Spores were found in the middle layers and were collected. They were washed with 10 ml water for three times. The total obtained number of viable spores per ml was determined by serial dilution, plating on TSA, and counting CFUs. The total number of heat-resistant spores per ml was determined by submerging the spores in water bath at 80 °C for 20 min followed by serial dilution and quantification of CFU/ml as described above.

Murine intestinal colonization model {#S19}
------------------------------------

*In-vivo* studies were approved by the Institutional Animal Care and Use Committee of the NIAID. Animal work was conducted adhering to the institution's guidelines for animal use, and followed the guidelines and basic principles in the United States Public Health Service Policy on Humane Care and Use of Laboratory Animals, and the Guide for the Care and Use of Laboratory Animals by certified staff in an Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International accredited facility.

All C57BL/6J mice were female and six to eight weeks of age at the time of use. In one setup, before *S. aureus* was given by oral gavage, mice were pre-treated to eradicate the pre-existing intestinal microbiota using an antibiotic mix consisting of ampicillin (1 g/l), metronidazole (1 g/l), neomycin trisulfate (1 g/l), and vancomycin (1 g/l), in the drinking water. The last day before gavage, antibiotics were omitted from the drinking water. No bacteria could be found in the feces or intestines of mice for 7 days after this treatment in a control experiment. In another setup, antibiotic pre-treatment was omitted. In all setups, *S. aureus* strains were grown to mid-exponential growth phase, washed, and resuspended in sterile PBS at 10^8^ CFU/ml. Mice were inoculated by oral gavage with 200 μl of a 10^8^ CFU/ml suspension of the indicated *S. aureus* strains, or 1:1 mixtures of wild-type and isogenic *agr* mutants to reach the same final concentration and volume. For the experiments with pKX~Δ~ plasmid-containing strains, mice received kanamycin (0.2 g/l) in the drinking water during the experiment to maintain plasmids. For the *B. subtilis* spore competition experiment, oral gavage with 200 μl of spores of the *Bacillus* wild-type or its isogenic Δ*fenA* fengycin mutant (10^8^ CFU/ml in sterile PBS) was performed on the day following the *S. aureus* gavage, and repeated every second day thereafter for a total of 3 times (days 2, 4, and 6). Intestinal colonization was evaluated by quantitative cultures of mice stool samples and samples from the small and large intestine. In detail, stool was collected and suspended to a final volume of 1 ml of PBS, diluted, and plated on TSB agar. Plates were incubated for 24 h at 37 °C, and colonies were enumerated. Moreover, after mice were euthanized seven days after infection, the small and large intestines were collected, resuspended each in 1 ml PBS, and homogenized. Serial dilutions of the homogenates were plated on TSB agar and incubated at 37 °C. Bacterial colonies were enumerated on the following day. In the experiments without antibiotic pre-treatment, extracts were plated on MSA plates containing 4 μg/ml oxacillin (for strain USA300 LAC) or 3 μg/ml tetracycline (for tetracycline-resistant derivatives of ST88 and ST2196), incubated for 48 h at 37 °C, and enumerated.

Statistics {#S20}
----------

Statistical analysis was performed using GraphPad Prism Version 6.05 using 1-way or 2-way ANOVA, or Fisher's exact test, as appropriate, except for the experiments shown in Figures [2c](#F2){ref-type="fig"}, [5b,c](#F5){ref-type="fig"}, and Extended Data Figs. [2 b,c](#F7){ref-type="fig"}and [5c-f](#F10){ref-type="fig"}, for which Stata Release 15 and Poisson regression was used, due to the exclusive presence of 0 values in one group (no variance). In ANOVAs, Tukey post-tests were used, which correct for multiple comparisons using statistical hypothesis testing. All error bars show the mean and standard deviation (SD). All replicates are biological.

Data availability {#S21}
-----------------

Microbiome sequencing data are available at <http://www.ncbi.nlm.nih.gov/bioproject/483343>. All other data generated or analyzed during this study are included in this published article or in the supplementary information files.

Supplementary Material {#SM1}
======================

Extended Data {#S22}
=============

![Microbiome analysis of *S. aureus* carriers versus non-carriers.\
The microbiota of n=20 randomly selected *S. aureus* carriers (red) and n=20 non-carriers (blue) were analyzed in fecal samples. **a-c**, Rarefaction curves of 16S rRNA gene sequences. Error bars shown the means ±SD. **a**, Shannon index. **b**, Observed species against the number of sequences per sample. **c**, Chao1 index. **d**, Relative taxa abundance comparison between *S. aureus* carriers (red) and non-carriers (blue), **e-f,** beta diversity, represented by a Principal Coordinate Analysis (PCoA) plot based on unweighted UniFrac **(e)** and weighted UniFrac metrics **(f)** for samples from *S. aureus* carriers (red) and non-carriers (blue).](nihms-1503935-f0006){#F6}

![Quorum-sensing dependence of *S. aureus* intestinal colonization.\
Data from strains USA300 LAC and ST88 JSNZ. The experimental setup is the same as in **[Fig. 2](#F2){ref-type="fig"}** of the main manuscript: Mice received by oral gavage 100 μl containing 10^8^ CFU/ml of wild-type (WT) *S. aureus* strains USA300 LAC or ST88 JSNZ and another 100 μl of 10^8^ CFU/ml of the corresponding isogenic *agr* mutant (n=5/group, competitive experiment shown in **a,b**), or 200 μl containing 10^8^ CFU/ml wild-type, isogenic *agr* mutant, or Agr (RNAIII)-complemented *agr* mutant (n=5/group, non-competitive experiment shown in **c**). CFU in the feces were determined two, four, and six days after infection. At the end of the experiment (day seven), CFU in the small and large intestines were determined. **a**,**b** Competitive experiment. Total obtained CFU are shown as dot plots, also showing the means ±SD. Bars show the percentage of wild-type among total determined CFU, of which 100 were analyzed for tetracycline resistance that is present only in the *agr* mutant. No *agr* mutants were detected in any experiment; thus, all bars show 100%. Given that 100 isolates were tested, the competitive index wild-type/*agr* mutant in all cases is ≥ 100. **c**, Non-competitive experiment with genetically complemented strains. Wild-type and isogenic *agr* mutant strains all harbored the pKX~Δ~16 control plasmid; Agr-complemented strains harbored pKX~Δ~RNAIII, constitutively expressing RNAIII, which is the intracellular effector of Agr. During the experiment, mice received 200 μg/ml kanamycin in the drinking water to maintain plasmids. Statistical analysis was performed using Poisson regression versus values obtained with the *agr* mutant strains. \*, p\<0.0001. Error bars show the means ±SD. Note no bacteria were found in the feces or intestines of any mouse receiving *S. aureus* Δ*agr* with vector control. The corresponding zero values are plotted on the x-axis of the logarithmic scale.](nihms-1503935-f0007){#F7}

![Analysis of Agr-inhibitory substances.\
**a**, Influence of heat and protease on Agr inhibition. *B. subtilis* (*B. s*.) culture filtrate was subjected to heat (95 °C, 20 min) or proteinase K digestion (50 μg/ml, 37 °C, 1 h) and the impact on inhibition of Agr activity was measured using the luminescence assay with the USA300 P3-*luxABCDE* reporter strain (see [Fig. 3a](#F3){ref-type="fig"}). RLU, relative light units. The experiment was performed with n=2 independent biological samples. Lines connect the means. (The observed additional suppression of Agr activity in the proteinase K-treated sample at 6 h, as compared to the *B.s.* culture filtrate sample, is expected due to proteolytic inactivation of intrinsic AIP.) **b**, Preparative RP chromatography of *B. subtilis* culture filtrate to determine the Agr-inhibiting substance. The peaks labeled 2 and 3 showed significant Agr-inhibiting activities in the Agr activity assay and were identified as fengycins using subsequent RP-HPLC/ESI-MS and MS/MS analysis (see **c**,**d**). The peaks labeled 1 and 4--6 also contained fengycin species (see **e**). **c**, Fractions corresponding to the Agr-inhibitory peaks 2 and 3 from the preparative RP run (**b**) were subjected to RP-HPLC/ESI-MS. Top, total ion chromatograms (TICs) of the RP-HPLC/ESI-MS runs; bottom, ESI mass spectrogram of the major peaks. **d**, MS/MS analysis of the peak 2 and 3 fractions. Peaks that are characteristic for a given fengycin subtype (A or B in this case) are marked in color. **e,** Analysis of further fengycin-containing fractions. Peaks 1, 4, 5, and 6 from the preparative RP run (**b**) were also found to contain fengycin species as determined by subsequent RP-HPLC/ESI-MS analysis. Shown are the mass spectrograms of the major peaks of those runs and the tentative characterization for fengycin type. The preparative and analytical chromatography and HPLC/MS analyses (as shown in **b** and **d**) were repeated multiple (\> 10) times for fengycin purification with similar results. MS/MS analyses were not repeated. **f**, Analysis of fengycin and surfactin lipopeptide expression of the *B. subtilis* wild-type strain and its isogenic Δ*fenA* mutant.](nihms-1503935-f0008){#F8}

![Assessment of purity and functionality of purified β-OH-C17-Fengycin B.\
**a**, RP-HPLC run. **b**, Agr inhibition at different concentrations in the luminescence assay. RLU, relative light units. Statistical analysis was by 2-way ANOVA with Tukey's post-test. Comparisons shown are those versus DMSO control. **c**, Agr inhibition as measured by inhibition of expression of RNAIII by qRT-PCR. \*, p\<0.0001 (1-way ANOVA with Tukey's post-test. Comparisons shown are those versus 0 μM value). **b**,**c**, The experiments were performed with n=3 independent biological samples. Error bars show the means ±SD.](nihms-1503935-f0009){#F9}

![Inhibition of *S. aureus* colonization by dietary fengycin-producing *Bacillus* spores in a mouse model.\
**a,** AIP concentration during *S. aureus* growth. Strain LAC (USA300) was grown in TSB and AIP concentrations were measured by HPLC/MS. Calibration was performed using synthetic AIP. The detection limit of this assay is \~ 0.3 μM. The experiment was performed with n=3 independent biological samples. Error bars show the means ±SD. **b**, *B. subtilis* colonization kinetics in the mouse intestinal colonization experiment. Mice (n=5) received 200 μl of a 10^8^ CFU/ml suspension of *B. subtilis* wild-type or Δ*fenA* mutant spores by oral gavage and CFU in the feces were analyzed up to 5 days afterwards. Error bars show the means ±SD. **c-f**, Inhibition mouse model with strains USA300 LAC and ST88 JSNZ. The experimental setup was the same as shown in [Fig. 5a](#F5){ref-type="fig"}. n=4 or 5 mice/group received 200 μl of 10^8^ CFU/ml *S. aureus* strains USA300 LAC or ST88 JSNZ by oral gavage. On the next and every following second day, they received 200 μl of 10^8^ CFU/ml spores of the *B. subtilis* wild-type (WT) or its isogenic *fenA* mutant, also by oral gavage. CFU in the feces were determined two, four, and six days after infection. At the end of the experiment (day seven), CFU in the small and large intestines were determined. The experiment was performed with (**c**,**d**) or without (**e**,**f**) antibiotic pre-treatment. Statistical analysis was performed using Poisson regression versus values obtained with the *B. subtilis* WT spore samples. \*, p\<0.0001. Error bars shown the means ±SD. Note no *S. aureus* were found in the feces or intestines of any mouse challenged with any *S. aureus* strain receiving *Bacillus* wild-type spores. The corresponding zero values are plotted on the x-axis of the logarithmic scale.](nihms-1503935-f0010){#F10}

###### 

Fengycin production and Agr inhibitory potency of *Bacillus* fecal isolates[\*](#TFN1){ref-type="table-fn"}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Isolate\   *Bacillus* species^[†](#TFN2){ref-type="table-fn"}^   β - OH-C16- FenA   C16-FenA   β - OH-C17- FenB   C17-FenB   β - OH-C17- FenA   C17-FenA   β - OH-C16- FenB   C16-FenB   \% Agr inhibition^[‡](#TFN3){ref-type="table-fn"}^   Total Fengycin Concentration
  Code                                                                                                                                                                                                                                          
  ---------- ----------------------------------------------------- ------------------ ---------- ------------------ ---------- ------------------ ---------- ------------------ ---------- ---------------------------------------------------- ------------------------------
  10         *licheniformis*                                       100                48         65                 80         33                 33         51                 32         98                                                   442

  14         *subtilis*                                            82                 27         104                138        52                 111        186                0          97                                                   700

  15         *amyloliquefaciens*                                   7                  212        212                83         152                56         274                81         92                                                   1076

  16         *sonorensis*                                          5833               437        984                288        2751               1248       1760               1090       98                                                   14390

  18         *subtilis*                                            107                0          58                 118        0                  0          53                 23         97                                                   359

  19         *ticheniformis*                                       0                  61         0                  75         13                 0          149                31         97                                                   329

  21         *sonorensis*                                          0                  85         159                48         0                  104        18                 33         95                                                   447

  26         *megaterium*                                          47                 0          112                8          33                 134        48                 23         98                                                   405

  30         *subtilis*                                            0                  0          63                 28         109                77         87                 43         96                                                   407

  31         *sonorensis*                                          23                 0          52                 0          157                15         0                  0          97                                                   246

  32         *sonorensis*                                          23                 118        145                0          0                  0          74                 59         94                                                   418

  33         *ticheniformis*                                       89                 119        70                 99         98                 102        150                0          96                                                   727

  35         *ticheniformis*                                       0                  0          98                 0          149                72         28                 132        96                                                   479

  36         *pumilus*                                             0                  0          10                 0          0                  136        144                0          98                                                   290

  37         *subtilis*                                            116                232        67                 0          15                 45         0                  114        96                                                   589

  38         *subtilis*                                            59                 167        215                0          79                 114        50                 212        93                                                   896

  39         *ticheniformis*                                       150                117        249                0          241                271        226                230        96                                                   1484

  40         *subtilis*                                            753                174        1260               1124       1548               538        841                821        80                                                   7058

  41         *subtilis*                                            2298               860        1777               0          4524               816        1563               1957       91                                                   13796

  42         *sonorensis*                                          34                 43         0                  0          41                 57         88                 0          96                                                   263

  43         *sonorensis*                                          477                0          2488               816        1667               604        1216               858        96                                                   8126

  45         *sonorensis*                                          98                 0          24                 25         0                  0          0                  39         99                                                   187

  47         *pumilus*                                             342                14         237                0          0                  108        105                0          97                                                   806

  48         *subtilis*                                            0                  0          49                 0          7                  0          0                  0          94                                                   56

  49         *subtilis*                                            5007               828        979                0          3147               0          2027               1210       97                                                   13200

  50         *subtilis*                                            429                0          933                0          1065               354        614                526        90                                                   3922

  51         *subtilis*                                            712                185        911                208        1187               665        863                586        88                                                   5316

  52         *subtilis*                                            9630               1571       923                0          2365               1775       4690               1099       95                                                   22052

  53         *ticheniformis*                                       0                  0          0                  0          0                  0          58                 25         95                                                   83

  55         *subtilis*                                            45                 43         113                12         94                 0          0                  216        96                                                   523

  56         *sonorensis*                                          167                53         0                  0          83                 201        109                58         98                                                   671

  57         *subtilis*                                            127                104        166                301        61                 96         98                 246        96                                                   1200

  58         *sonorensis*                                          498                510        841                0          967                222        0                  0          94                                                   3039

  59         *subtilis*                                            0                  0          1008               0          0                  297        715                488        82                                                   2508

  61         *subtilis*                                            124                84         21                 0          160                39         42                 335        97                                                   805

  62         *ticheniformis*                                       93                 128        7                  48         40                 188        0                  153        97                                                   657

  63         *amyloliquefaciens*                                   4153               380        975                0          2584               1047       1975               1084       95                                                   12197

  64         *sonorensis*                                          133                91         187                230        29                 387        62                 34         95                                                   1154

  65         *subtilis*                                            9                  126        0                  0          35                 90         239                36         97                                                   535

  66         *sonorensis*                                          254                0          0                  0          377                0          131                0          97                                                   762

  67         *subtilis*                                            215                84         200                0          0                  0          155                168        97                                                   821

  68         *subtilis*                                            41                 12         144                0          0                  0          115                182        93                                                   494

  69         *subtilis*                                            266                27         236                290        132                0          54                 195        98                                                   1200

  70         *subtilis*                                            54                 55         390                0          196                0          187                112        94                                                   994

  71         *subtilis*                                            14881              4578       88106              34879      39939              16967      42502              23859      97                                                   265710

  74         *pumilus*                                             157                56         54                 14         0                  62         177                41         95                                                   560

  75         *ticheniformis*                                       281                22         40                 0          0                  292        125                204        95                                                   964

  76         *subtilis*                                            124                0          74                 0          0                  101        82                 192        97                                                   573

  77         *sonorensis*                                          0                  0          0                  25         0                  0          93                 13         97                                                   131

  78         *amyloliquefaciens*                                   73                 99         0                  0          79                 17         176                13         94                                                   458

  79         *amyloliquefaciens*                                   10                 0          0                  0          0                  180        51                 63         97                                                   304

  80         *subtilis*                                            1741               322        4222               1105       3327               910        2207               1529       91                                                   15363

  81         *subtilis*                                            1739               426        5073               1579       3371               998        3241               1933       87                                                   18361

  82         *subtilis*                                            1002               0          3413               921        1998               0          1710               992        91                                                   10037

  83         *ticheniformis*                                       356                0          536                4          83                 201        107                52         97                                                   1338

  85         *subtilis*                                            52                 0          49                 0          84                 161        0                  132        95                                                   479

  87         *subtilis*                                            1327               312        3931               0          2763               667        2624               1167       98                                                   12790

  88         *pumilus*                                             101                0          215                156        313                367        276                216        96                                                   1643

  89         *subtilis*                                            105                59         266                0          0                  0          51                 38         93                                                   519

  91         *subtilis*                                            325                91         493                17         120                290        302                186        98                                                   1825

  92         *subtilis*                                            254                0          234                156        275                0          154                66         96                                                   1140

  93         *subtilis*                                            493                273        91                 342        204                287        277                435        96                                                   2402

  94         *subtilis*                                            876                115        134                37         384                190        445                529        91                                                   2712

  95         *amyloliquefaciens*                                   351                175        157                146        110                225        196                197        97                                                   1557

  97         *subtilis*                                            1845               912        4714               1310       3686               1492       2484               1557       86                                                   18000

  98         *subtilis*                                            1367               804        3572               1512       2803               1511       2005               1626       93                                                   15200

  99         *subtilis*                                            77                 375        705                0          28                 170        115                77         91                                                   1547

  100        *amyloliquefaciens*                                   81                 117        337                267        105                166        237                502        81                                                   1811

  103        *pumilus*                                             249                45         350                207        162                249        536                279        98                                                   2077

  104        *subtilis*                                            293                77         105                269        75                 509        286                17         99                                                   1632

  106        *subtilis*                                            978                796        4415               3419       1874               1378       2478               1527       97                                                   16866

  107        *subtilis*                                            423                199        322                150        520                517        384                160        98                                                   2675

  108        *pumilus*                                             224                114        397                0          229                211        413                43         99                                                   1631

  110        *subtilis*                                            140                77         317                286        404                127        117                139        95                                                   1607

  111        *pumilus*                                             184                104        319                67         96                 212        294                120        93                                                   1395

  112        *subtilis*                                            470                183        1412               637        1211               732        950                655        96                                                   6251

  113        *pumilus*                                             463                202        276                204        211                0          156                137        95                                                   1650

  115        *subtilis*                                            268                232        297                62         313                410        713                88         97                                                   2382

  116        *subtilis*                                            352                205        369                0          172                298        561                350        96                                                   2306

  117        *subtilis*                                            143                104        716                328        0                  149        97                 266        98                                                   1803

  118        *subtilis*                                            163                34         1788               0          0                  155        306                42         93                                                   2488

  119        *amyloliquefaciens*                                   604                256        947                258        0                  350        361                104        93                                                   2880

  121        *subtilis*                                            503                151        0                  364        63                 84         174                162        98                                                   1502

  122        *subtilis*                                            152                311        24                 165        86                 213        296                83         91                                                   1329

  123        *subtilis*                                            8801               3540       23045              10778      16465              6428       16077              10706      98                                                   95839

  124        *subtilis*                                            106                139        316                168        64                 175        195                103        86                                                   1266

  125        *subtilis*                                            0                  0          0                  158        0                  318        290                0          95                                                   765

  126        *subtilis*                                            288                157        211                110        428                421        185                112        87                                                   1913

  127        *subtilis*                                            478                193        103                435        240                303        551                132        96                                                   2434

  128        *subtilis*                                            177                156        228                118        96                 276        426                48         97                                                   1525

  129        *pumilus*                                             249                37         0                  162        0                  224        0                  144        97                                                   816

  130        *subtilis*                                            1267               0          4668               1266       2940               1168       2158               1863       88                                                   15332

  131        *subtilis*                                            4164               496        513                307        1226               671        1948               662        83                                                   9986

  132        *subtilis*                                            441                291        491                391        200                562        381                279        95                                                   3036

  134        *subtilis*                                            6647               750        1011               0          3143               1166       2829               953        97                                                   16498

  136        *subtilis*                                            751                233        2569               773        1813               890        1701               1010       89                                                   9740

  137        *subtilis*                                            1572               328        3297               1036       2221               627        2266               0          82                                                   11347

  138        *pumilus*                                             288                311        232                11         415                236        236                403        85                                                   2133

  139        *subtilis*                                            1898               709        7830               2453       5328               2073       3880               2210       98                                                   26381

  140        *sonorensis*                                          0                  106        217                815        225                0          103                3987       91                                                   5454

  141        *thuringiensis*                                       258                26         325                230        0                  264        0                  0          87                                                   1102

  142        *pumilus*                                             422                159        262                0          402                335        639                251        87                                                   2471

  143        *subtilis*                                            250                37         210                16         64                 68         293                89         83                                                   1027

  144        *sonorensis*                                          110                208        134                191        0                  304        361                91         87                                                   1399

             *B. subtilis* ZK3814                                  2563               1781       17078              5725       11963              4448       5444               4902       94                                                   53904
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The table shows intensity values of the integration of m/z peaks associated with the specific fengycin species as obtained by HPLC/MS. The two most abundant peaks, corresponding to double and triple charged ions, were used for the integration. Values are in nM, obtained by calibration using weighed and diluted aliquots of the *Bacillus* lipopeptide surfactin.

*Bacillus* species were determined by sequencing 16S RNA encoding DNA, as specified in Methods.

Percentage of Agr inhibition was determined by dividing the 4-h value in the luminescence assay (using 100 μl of culture filtrate) obtained for the sample by that obtained for the control and multiplying by 100.

###### 

Analysis of previous microbiome studies[\*](#TFN4){ref-type="table-fn"} for correlation between *S. aureus* and *B. subtilis* presence in the human intestinal tract

  Study ID    Study Name                                                                                                           Samples   Only *B. subtilis*   Only S. aureus   Both           Neither
  ----------- -------------------------------------------------------------------------------------------------------------------- --------- -------------------- ---------------- -------------- ---------------
  ERP012803   American Gut Project                                                                                                 6635      1 (0.015%)           304 (4.58%)      0              6330 (95.4%)
  ERP011001   Human gut bacteria that rescue growth and metabolic defects transmitted by microbiota from undernourished children   1732      408 (23.61%)         70 (4.05%)       71 (4.11%)     1179 (68.23%)
  ERP005437   16S sequencing of Malawian children                                                                                  1515      118 (7.79%)          6 (0.4%)         4 (0.26%)      1387 (91.55%)
  SRP049113   Human gut microbiota from the ALADDIN study                                                                          664       2 (0.30%)            61 (9.19%)       7(1.05%)       594 (89.46%)
  ERP019564   Role of Gut Microbiota in Pathophysiology of Parkinson\'s Disease                                                    481       8(1.66%)             7(1.45%)         0              466 (96.88%)
  SRP073172   DNA from FIT can replace stool for microbiota-based colorectal                                                       408       63 (15.44%)          71 (17.40%)      99 (24.26%)    175 (42.89%)
  SRP068240   Human feces metagenome 16s rDNA sequencing                                                                           350       52 (14.85%)          189 (54%)        89 (25.43%)    20 (5.71%)
  SRP064846   Homo sapiens fecal microbiome transplant                                                                             271       20 (7.38%)           47 (17.34%)      6(2.21%)       198 (73.06%)
  SRP065497   Human gut environment Targeted loci environmental                                                                    270       54 (20%)             8 (2.96%)        19 (7.04%)     189 (70%)
  ERP021093   Gut microbiome from patients obtained by 16s rRNA sequencing.                                                        268       88 (32.84%)          14 (5.22%)       57 (21.27%)    109 (40.67%)
  ERP010229   Gut microbial succession follows acute secretory diarrhea in humans                                                  260       12 (4.62%)           92 (35.38%)      122 (46.92%)   34 (13.08%)
  ERP010458   Gut microbiota of stroke patients differentiates from healthy controls                                               233       3(1.29%)             32 (13.73%)      4(1.72%)       194 (83.26%)

Inclusion criteria: All studies found on the EBI Metagenomics website (<https://www.ebi.ac.uk/metagenomics/>) with \> 200 participants (independent samples) using Illumina Miseq instruments were included in the analysis.

Analysis: Raw 16S rRNA sequencing data were pooled from the EBI Metagenomics website. Taxonomic assignment (TSV) files were used for analysis. The number of sequence reads was used to analyze how many samples contain *S. aureus* or *B. subtilis*. Samples with a read number of more than 0 were defined as colonized. When there were no reads, samples were designated as non-colonized.
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![*S. aureus* colonization exclusion by dietary *Bacillus* in a human population.\
**a**, Areas (in red) from which fecal samples were collected in rural populations and analyzed for presence of *Bacillus* and *S. aureus*. **b,c**, Intestinal (**b**) and nasal (**c**) colonization with *S. aureus* (yellow) in individuals that showed (green) or did not show (grey) intestinal colonization with *Bacillus*.](nihms-1503935-f0001){#F1}

![Quorum-sensing dependence of *S. aureus* intestinal colonization.\
**a**, Experimental setup of the murine intestinal colonization model. Mice received by oral gavage 100 μl containing 10^8^ CFU/ml of wild-type (WT) *S. aureus* strain ST2196 F12 and another 100 μl of 10^8^ CFU/ml of the corresponding isogenic *agr* mutant (n=5/group, competitive experiment shown in **b**), or 200 μl containing 10^8^ CFU/ml wild-type, isogenic *agr* mutant, or Agr (RNAIII)-complemented *agr* mutant (n=5/group, non-competitive experiment shown in **c**). CFU in the feces were determined two, four, and six days after infection. At the end of the experiment (day seven), CFU in the small and large intestines were determined. **b**, Competitive experiment. Total obtained CFU are shown as dot plots, also showing the means ±SD. Bars show the percentage of wild-type among total determined CFU, of which 100 were analyzed for tetracycline resistance that is present only in the *agr* mutant. No *agr* mutants were detected in any experiment; thus, all bars show 100%. Given that 100 isolates were tested, the competitive index wild-type/*agr* mutant in all cases is ≥ 100. **c**, Non-competitive experiment with genetically complemented strains. Wild-type and isogenic *agr* mutant strains all harbored the pKX~Δ~16 control plasmid; Agr-complemented strains harbored pKX~Δ~RNAIII, constitutively expressing RNAIII, which is the intracellular effector of Agr. During the experiment, mice received 200 μg/ml kanamycin in the drinking water to maintain plasmids. Statistical analysis was performed using Poisson regression versus values obtained with the *agr* mutant strains. \*, p\<0.0001. Error bars shown the means ±SD. Note no bacteria were found in the feces or intestines of any mouse receiving *S. aureus* Δ*agr* with vector control. The corresponding zero values are plotted on the x-axis of the logarithmic scale. See [Extended Data Fig. 2](#F7){ref-type="fig"} for the corresponding data using strains USA300 LAC and ST88 JSNZ.](nihms-1503935-f0002){#F2}

![*S. aureus* quorum-sensing inhibition by *Bacillus* fengycin lipopeptides.\
**a,** Example of an Agr inhibition experiment. The *Bacillus* isolate was considered inhibitory if luminescence after 4 h growth of *S. aureus* was ≤ 0.5 times that of the control value. RLU, relative light units. The experiment was performed with n=2 biologically independent samples. The lines connect the means. **b**, Inhibition of expression of PVL and α-toxin, using culture filtrate of the *B. subtilis* reference strain. Western blot analysis of n=3 biologically independent samples was performed with *S. aureus* culture filtrates grown for 4 h. See [Supplementary Fig. 1](#SD3){ref-type="supplementary-material"} **f**or the entire blots. **c**, Inhibition of expression of PSM toxins using culture filtrate of the *B. subtilis* standard strain. PSM expression was determined by RP-HPLC/ESI-MS after 4 h of growth. **d**, Test for inhibitory capacity of *Bacillus* culture filtrate applied to a final concentration representing the median concentration of total fengycin in the tested 106 *Bacillus* isolates. \*, p\<0.0001 (2-way ANOVA with Tukey's post-test versus control). **e**, Total fengycin concentrations in stationary-phase culture filtrates of the 106 *Bacillus* isolates (see [Extended Data Table 1](#F6){ref-type="fig"} for details). **f**, Agr-inhibiting activities of *B. subtilis* wild-type (WT) in comparison to Δ*fenA* (fengycin-deficient) and Δ*srfA* (surfactin-deficient) strains. \*, p\<0.0001 (2-way ANOVA with Tukey's post-test versus WT). **c,d,f**, The experiments were performed with n=3 biologically independent samples. Error bars shown the means ±SD.](nihms-1503935-f0003){#F3}

![Competitive inhibition of *S. aureus* AIP activity by fengycins.\
**a**, Model of competitive Agr inhibition by fengycins. The *agrBDCA* operon, whose expression is driven by the P2 promoter, encodes the AgrD precursor of the autoinducing peptide (AIP), which is modified and secreted by AgrB. AIP binds to membrane-located AgrC, which upon auto-phosphorylation triggers phosphorylation and activation of the DNA-binding protein, AgrA. In addition to stimulating transcription from the P2 promoter (auto-induction), AgrA drives expression of RNAIII, which in turn regulates expression of target genes. RNAIII also encodes the δ-toxin. Furthermore, AgrA drives PSM expression in an RNAIII-independent fashion. **b**, Structural similarity of fengycins with AIPs. The structures of β-OH-C17-Fengycin B and AIP-I are shown as examples. In red are structures/amino acids that may differ in different subtypes. **c**, Fengycins work by inhibition of AgrC. Shown is the Agr inhibition by fengycin-containing *Bacillus* culture filtrate using an *agrBD*-deleted strain in which AgrC was stimulated by exogenously added AIP. \* p\<0.0001 \[2-way ANOVA with Tukey's post-test: Values obtained in Δ*agrBD*/AIP versus Δ*agrBD*/control (no AIP) and Δ*agrBD*/AIP/culture filtrate versus Δ*agrBD*/AIP\]. **d**, Competitive titration of fengycin-mediated Agr inhibition by increasing amounts of AIP as assayed by the Agr luminescence assay. RLU, relative light units. Statistical analysis is by 2-way ANOVA with Tukey's post-test versus control. **e**, Inhibition of Agr in different Agr subtype *S. aureus* and *S. epidermidis* (strain 1457) by β-OH-C17-Fengycin B as measured by relative expression of δ-toxin via RP/HPLC-MS. Statistical analysis is by 2-way ANOVA with Tukey's post-test versus intensity values obtained without addition of fengycin. Values were calculated as percentage relative to intensity values obtained without addition of fengycin, due to different δ-toxin expression levels in the different strains. **c-e**, The experiments were performed with n=3 biologically independent samples. Error bars shown the means ±SD.](nihms-1503935-f0004){#F4}

![Inhibition of *S. aureus* colonization by dietary fengycin-producing *Bacillus* spores in a mouse model.\
**a,** Experimental setup. n=5 mice/group received 200 μl of 10^8^ CFU/ml *S. aureus* strain ST2196 F12 by oral gavage. On the next and every following second day, they received 200 μl of 10^8^ CFU/ml spores of the *B. subtilis* wild-type (WT) or its isogenic *fenA* mutant, also by oral gavage. CFU in the feces were determined two, four, and six days after infection. At the end of the experiment (day seven), CFU in the small and large intestines were determined. The experiment was performed with (**b**) or without (**c**) antibiotic pre-treatment. **b**,**c** Results. Statistical analysis was performed using Poisson regression versus values obtained with the *B. subtilis* WT spore samples. \*, p\<0.0001. Error bars shown the means ±SD. Note no *S. aureus* were found in the feces or intestines of any mouse challenged with any *S. aureus* strain receiving *Bacillus* wild-type spores. The corresponding zero values are plotted on the x-axis of the logarithmic scale. See [Extended Data Fig. 5](#F10){ref-type="fig"} for the corresponding data using strains USA300 LAC and ST88 JSNZ.](nihms-1503935-f0005){#F5}
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